BillionToOne (BLLN) Q1 2026 Earnings Transcript

BillionToOne delivered Q1 2026 revenue of $108.4 million, up 84% year over year, with gross margin expanding to 73%, operating margin at 16%, and adjusted EBITDA margin at 24%. Management raised full-year 2026 revenue guidance to $445 million-$465 million from $425 million-$445 million, citing strong Q1 results and improved ASPs from new payer contracts including Anthem and UnitedHealthcare. The company also launched Unity Confirm and reiterated that gross margins should stay at or above 70% this year.

Analysis

BLLN is shifting from a single-product growth story to a platform with multiple compounding monetization layers. The key second-order effect is not the near-term revenue contribution from new launches, but the way product breadth tightens workflow lock-in: once a provider adopts the prenatal franchise, incremental upsell is getting easier while competitor displacement gets harder. Anthem plus the growing contract base should also reduce the volatility of collections and make ASP expansion look more linear, which matters because diagnostics multiple expansion usually follows revenue quality, not just top-line growth.

The most underappreciated margin lever is mix discipline, not raw test volume. Management is effectively telling us oncology is still a margin dilutive growth engine today, but every reimbursement or coverage step-up there can re-rate the whole company because fixed commercial infrastructure gets leveraged across both segments. That creates a path where gross margin can stay stubbornly above 70% even if oncology keeps outgrowing prenatal, so the market may be too focused on a hypothetical margin trough that never fully arrives.

The main risk is that the street extrapolates early-year ASP and true-up behavior too aggressively into the back half. If payer contracting slows or collections lag longer than expected, the combination of high expectations, launch-heavy SG&A, and a slower seasonal Q4 could compress sentiment quickly even if the fundamental trajectory remains intact. Another hidden risk is execution on Unity Confirm: it sounds strategically important, but its direct TAM contribution is tiny, so any disappointment would only hurt if investors mistakenly capitalize it as a near-term revenue driver rather than a differentiation tool.

Consensus may also be underestimating how much of the bull case now depends on maintaining product cadence and reimbursement momentum simultaneously. That is a higher bar than simple volume growth, but it also creates a longer runway if they keep hitting on launches and payer wins. In that sense, this is less a one-quarter beat story and more an emerging recurring re-rating candidate if the company proves it can stack 70%+ gross margin on top of 40%+ growth for several more quarters.

Key Decisions for Investors

• Long BLLN on a 3-6 month horizon on pullbacks after the post-earnings move; risk/reward remains favorable if the market underwrites 2026 revenue closer to the new guide with 70%+ gross margins, but trim if management signals ASP growth is decelerating before Q3.
• Sell downside via BLLN put spreads into volatility if available; the setup supports elevated implied volatility, and the stock is more likely to re-rate on execution than collapse unless collections or payer momentum break.
• Pair trade: long BLLN / short a slower-growing diagnostics peer with lower gross margin durability and weaker reimbursement leverage; the thesis is that BLLN’s mix shift and contract momentum should keep outperformance intact over the next 2-4 quarters.
• Watch for a catalyst trade into the next reimbursement update on NorthStar Response; if Medicare timing slips past year-end, reduce exposure because oncology ASP expansion is the cleanest second-half surprise lever.
• Do not chase Unity Confirm as a standalone TAM story; treat it as an adoption enhancer. Only add aggressively if provider adoption data shows it is pulling new frontline prenatals rather than simply creating PR-driven excitement.